French National Database of Rare Dermatological Cancers

Launched by UNIVERSITY HOSPITAL, LILLE · Jul 4, 2017

Keywords

ClinConnect Summary

The CARADERM clinical trial is studying three rare types of skin cancers: Merkel cell carcinoma, advanced basal cell carcinoma that needs systemic treatment, and cutaneous adnexal carcinoma. The goal of the trial is to learn more about these cancers, including how often they occur, their characteristics, and how different treatments affect patients' outcomes. By gathering this information, researchers hope to identify factors that could help predict how these cancers behave and how well patients might respond to treatment.

To participate in this trial, individuals must have a confirmed diagnosis of one of the three cancers mentioned. It's open to all genders and age groups. Participants will be asked to share their medical history and may undergo various assessments as part of the study. This research is important because it aims to fill in gaps in our understanding of these rare cancers, which can lead to better care and treatment options for patients in the future. If someone is considering joining, it’s essential to know that participation is voluntary, and they can choose not to take part at any time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma
• Exclusion Criteria:
• • Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma
• • Patients refusal